The historical rank and industry rank for Checkpoint Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 9 years, Checkpoint Therapeutics's highest Price to Tangible Book Ratio was 8.84. The lowest was 4.93. And the median was 5.65.
CKPT's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.7 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Checkpoint Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Checkpoint Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Checkpoint Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Checkpoint Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Checkpoint Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Checkpoint Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Checkpoint Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Checkpoint Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CKPT has been successfully added to your 